Medpace Holdings Inc
$ 423.93
-4.96%
11 Feb - close price
- Market Cap 12,654,787,000 USD
- Current Price $ 423.93
- High / Low $ 446.82 / 422.56
- Stock P/E 29.21
- Book Value 16.22
- EPS 15.27
- Next Earning Report 2026-04-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.16 %
- ROE 0.70 %
- 52 Week High 628.92
- 52 Week Low 250.05
About
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Analyst Target Price
$535.83
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-09 | 2025-10-22 | 2025-07-21 | 2025-04-21 | 2025-02-10 | 2024-10-21 | 2024-07-22 | 2024-04-22 | 2024-02-12 | 2023-10-23 | 2023-07-24 | 2023-04-24 |
| Reported EPS | 4.67 | 3.86 | 3.103 | 3.67 | 3.6813 | 3.01 | 2.75 | 3.2 | 2.46 | 2.22 | 1.93 | 2.27 |
| Estimated EPS | 4.18 | 3.53 | 2.99 | 3.0775 | 3.1167 | 2.78 | 2.54 | 2.47 | 2.22 | 2.05 | 1.91 | 1.8 |
| Surprise | 0.49 | 0.33 | 0.113 | 0.5925 | 0.5646 | 0.23 | 0.21 | 0.73 | 0.24 | 0.17 | 0.02 | 0.47 |
| Surprise Percentage | 11.7225% | 9.3484% | 3.7793% | 19.2526% | 18.1153% | 8.2734% | 8.2677% | 29.5547% | 10.8108% | 8.2927% | 1.0471% | 26.1111% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-27 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 3.92 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MEDP
2026-02-11 12:57:46
Madison Asset Management LLC reduced its stake in Medpace Holdings, Inc. by 1.5% in the third quarter, selling 4,419 shares and now holding 292,629 shares valued at $150.5 million. This aligns with significant insider selling from Medpace's CEO and VP, despite the company beating Q4 earnings and revenue estimates and raising its FY2026 guidance. The stock experienced a dip due to concerns about backlog normalization and timing shifts in metabolic trials, leading analysts to maintain a "Hold" rating with an average target price of $486.82.
2026-02-11 06:57:46
Medpace Holdings, Inc. reported strong Q4 2025 financial results, exceeding analyst estimates with significant revenue and GAAP net income growth. However, the positive earnings were tempered by an unexpected spike in project cancellations, particularly in the Metabolic therapeutic area, which led to a lower-than-anticipated net book-to-bill ratio. Management acknowledged the elevated cancellations but expressed hope they would not continue, with CEO August Troendle stating, "Only time will tell."
2026-02-10 21:58:23
Leerink Partners has reduced its price target for Medpace (NASDAQ:MEDP) to $485.00 from $575.00 due to unexpectedly high cancellation rates in the fourth quarter, particularly in cardiometabolic trials. Despite this, Medpace maintains strong financial health and recently reported impressive Q4 2025 results that surpassed analyst expectations in earnings and revenue. The lowered price target reflects increased uncertainty despite management's view that the business environment is unchanged.
2026-02-10 20:58:23
U.S. stock markets closed mixed on Tuesday, with some indexes showing slight gains and others experiencing declines. Spotify Technology was identified as a leading stock, while Medpace Holdings lagged behind. This broad performance indicates a varied day for the American markets.
2026-02-10 18:58:23
Medpace Holdings Inc (NASDAQ:MEDP) reported strong Q4 FY25 results, beating analyst expectations with increased net new business awards and significant revenue growth for the full year. Despite a slight dip in EBITDA margin, the company ended 2025 with substantial cash reserves and repurchase activity. Medpace's 2026 revenue outlook is largely in line with market predictions.
2026-02-10 15:32:49
Medpace Holdings Inc. (MEDP) reported strong Q4 2025 results, exceeding analyst expectations with an EPS of $4.67 and revenue of $708.5 million. Despite these positive figures, the stock dropped sharply by 13.92% in premarket trading due to investor concerns over elevated cancellation rates, particularly in the metabolic sector. The company projects 2026 revenue growth of 8.9% to 12.8% and is focusing on AI applications while managing operational risks.
